Preoperative neutrophil to lymphocyte ratio predicts survival in patients with T1-2N0 colorectal cancer

被引:50
作者
Shin, Jun Sang [1 ]
Suh, Kwang Wook [1 ]
Oh, Seung Yeop [1 ]
机构
[1] Ajou Univ, Sch Med, Dept Surg, Suwon 443721, South Korea
关键词
neutrophil; lymphocyte; prognosis; colorectal cancer; RECTAL-CANCER; ADJUVANT TREATMENT; NODE METASTASIS; COLON-CANCER; RISK; T1; RESECTION; SURGERY;
D O I
10.1002/jso.24061
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
PurposeNeutrophil to lymphocyte ratio (NLR) is reported to be associated with prognosis of colorectal cancer. The aim of this study is to determine whether the NLR is a predictor of oncological outcomes in patients with stage I colorectal cancer who underwent curative surgery. MethodsTwo hundred sixty-nine patients with stage I colorectal cancer who underwent surgical resection between December 2003 and December 2011 were retrospectively reviewed. The cutoff for NLR was defined as three by maximizing log-rank test statistics. We compared patients with a low NLR and those with a high NLR in terms of survival. ResultsThe 5-year disease-free survival (DFS) and cancer-specific survival (CSS) rates were lower in patients with a high NLR compared to those with a low NLR in stage I colorectal cancer (89.5% vs. 97.4%, P=0.006; 94.0% vs. 98.9%, P=0.022). Cox multivariate analysis demonstrated that preoperative NLR was independently associated with DFS (HR, 5.216; 95%CI, 1.400-19.431; P=0.014) and CSS (HR, 6.190; 95%CI, 1.034-37.047; P=0.046) in patients with stage I colorectal cancer. ConclusionThe preoperative NLR is a prognostic factor predicting DFS and CSS in patients with stage I colorectal cancer who underwent curative surgery. J. Surg. Oncol. 2015;112:654-657. (c) 2015 Wiley Periodicals, Inc.
引用
收藏
页码:654 / 657
页数:4
相关论文
共 21 条
[1]
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[2]
[Anonymous], ANN SURG ONCOL
[3]
Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer [J].
Bajetta, E. ;
Floriani, I. ;
Di Bartolomeo, M. ;
Labianca, R. ;
Falcone, A. ;
Di Costanzo, F. ;
Comella, G. ;
Amadori, D. ;
Pinto, C. ;
Carlomagno, C. ;
Nitti, D. ;
Daniele, B. ;
Mini, E. ;
Poli, D. ;
Santoro, A. ;
Mosconi, S. ;
Casaretti, R. ;
Boni, C. ;
Pinotti, G. ;
Bidoli, P. ;
Landi, L. ;
Rosati, G. ;
Ravaioli, A. ;
Cantore, M. ;
Di Fabio, F. ;
Aitini, E. ;
Marchet, A. .
ANNALS OF ONCOLOGY, 2014, 25 (07) :1373-1378
[4]
Stage I rectal cancer: Identification of high-risk patients - Reply [J].
Blumberg, D .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 186 (05) :580-580
[5]
Systemic inflammatory response is a predictor of outcome in patients undergoing preoperative chemoradiation for locally advanced rectal cancer [J].
Carruthers, R. ;
Tho, L. M. ;
Brown, J. ;
Kakumanu, S. ;
McCartney, E. ;
McDonald, A. C. .
COLORECTAL DISEASE, 2012, 14 (10) :E701-E707
[6]
Prognostic factors affecting survival and recurrence of patients with pT1 and pT2 colorectal cancer [J].
Chok, Kenneth S. H. ;
Law, Wai Lun .
WORLD JOURNAL OF SURGERY, 2007, 31 (07) :1485-1490
[7]
Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer [J].
Chua, W. ;
Charles, K. A. ;
Baracos, V. E. ;
Clarke, S. J. .
BRITISH JOURNAL OF CANCER, 2011, 104 (08) :1288-1295
[8]
The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM [J].
Edge, Stephen B. ;
Compton, Carolyn C. .
ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) :1471-1474
[9]
Fang WL, 2005, HEPATO-GASTROENTEROL, V52, P1688
[10]
Giessen-Jung C, 2015, TUMOUR BIOL